Thursday, August 1, 2019 Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple Foods NIH and Partners to Assess Whether Omalizumab Can Reduce Allergic Reactions A new study to evaluate an experimental treatment for food allergy launched today. Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy in Food Allergic Children and Adults, or OUtMATCH, will test the ability of biweekly or monthly injections of omalizumab—alone or together with multi-allergen oral immunotherapy—to increase a person's ability to tolerate foods to which they are allergic. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107